Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flotufolastat F 18→

Flotufolastat F 18 Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
C63H99[18F]N12O25Si
Molecular weight
1470.631 g/mol
Drug class
18F-labelled prostate-specific membrane antigen (PSMA) PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. PET imaging detects tracer distribution to localise PSMA-expressing prostate cancer lesions; it is a diagnostic radiopharmaceutical, not a therapeutic PSMA inhibitor.
Indications / reported uses
  • PET imaging of PSMA-positive lesions in men with prostate cancer to localise disease for initial staging or suspected recurrence, in conjunction with other diagnostic evaluations under the US PYLARIFY-like? specific product label; use only for the approved product indication and patient group

Sources: NLM DailyMed — Flotufolastat F 18 (POSLUMA) · US FDA — Flotufolastat PET imaging information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flotufolastat F 18 Environmental Risk Assessment (ERA) (the Flotufolastat F 18 ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.